NM26-2198 for Atopic Dermatitis/Eczema
Trial Summary
What is the purpose of this trial?
This trial tests a new injectable drug called NM26-2198 in healthy people and those with moderate to severe atopic dermatitis. The goal is to check its safety, how the body processes it, and if it triggers any immune responses.
Will I have to stop taking my current medications?
The trial requires that participants do not use certain medications, including sedating antihistamines, systemic corticosteroids, and other immunosuppressive agents. If you are taking these, you may need to stop before joining the trial.
Research Team
Yellow Jersey Therapeutics AG Clinical trial
Principal Investigator
Yellow Jersey Therapeutics AG
Eligibility Criteria
Adults aged 18-55 with moderate-to-severe atopic dermatitis (AD) covering ≥10% of their body, who are not pregnant or breastfeeding and agree to use contraception. Participants must have specific scores on AD severity scales and be free from certain medications and conditions that could affect the trial results.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Single Ascending Dose (SAD) Treatment
Participants receive a single subcutaneous dose of NM26-2198 or placebo
Multiple Ascending Dose (MAD) Treatment
Participants receive multiple subcutaneous doses of NM26-2198 or placebo on Days 1, 8, 15, and 22
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- NM26-2198
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Yellow Jersey Therapeutics AG
Lead Sponsor
Numab Therapeutics AG
Lead Sponsor
Kaken Pharmaceutical Co., Ltd.
Collaborator